TransCode Therapeutics (NASDAQ: RNAZ) has released updated clinical data from its Phase 1a trial of TTX-MC138, an investigational RNA therapeutic for patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors. The results, detailed in a recent announcement, show promising disease control and safety outcomes that could signal a new avenue for treating difficult-to-treat cancers.
As of September 1, 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as their best overall response. Six patients remained progression-free at three months, while three continued to be progression-free at six, nine, and 12 months. The disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1. A post-hoc Growth Modulation Index (GMI) analysis found that six of 15 evaluable patients (40%) achieved a GMI greater than 1.3, indicating a progression-free interval at least 30% longer than with their immediately preceding therapy.
Safety data also appear favorable. A total of 98 doses had been administered as of September 1, with no dose-limiting toxicities reported and no treatment-emergent adverse events leading to treatment discontinuation, including at the highest evaluated dose of 4.8 mg/kg. Exploratory RNA-sequencing analysis identified treatment-associated immune effects that the company said support the observed clinical activity, although the small-sample biomarker findings require confirmation in larger studies.
TransCode is evaluating dose-expansion strategies and plans to continue assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity. The company’s lead candidate, TTX-MC138, targets microRNA-10b, a well-documented biomarker of metastasis, and is designed to treat metastatic tumors that overexpress this microRNA. TransCode also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells.
For investors and industry observers, these updated data could represent a meaningful step forward for TransCode, which is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The results may bolster confidence in the company’s approach and support further clinical development. The full press release is available at https://ibn.fm/mIBZR, and the latest news and updates relating to RNAZ can be found in the company’s newsroom at https://ibn.fm/RNAZ.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, visit BioMedWire.
These findings are important because they suggest that TTX-MC138 may offer clinical benefit for patients with advanced solid tumors who have limited treatment options. The high rate of stable disease and the absence of dose-limiting toxicities support further investigation. If confirmed in larger trials, TTX-MC138 could become a valuable addition to the immuno-oncology arsenal, potentially improving outcomes for patients with metastatic disease.
